Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Non-Current Assets (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Non-Current Assets for 6 consecutive years, with $17.0 million as the latest value for Q1 2023.

  • On a quarterly basis, Non-Current Assets fell 28.87% to $17.0 million in Q1 2023 year-over-year; TTM through Mar 2023 was $17.0 million, a 28.87% decrease, with the full-year FY2022 number at $17.8 million, down 19.64% from a year prior.
  • Non-Current Assets was $17.0 million for Q1 2023 at Marker Therapeutics, down from $17.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $23.9 million in Q1 2022 to a low of $872702.0 in Q4 2019.
  • A 5-year average of $14.3 million and a median of $18.2 million in 2020 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 2329.69% in 2020, then decreased 28.87% in 2023.
  • Marker Therapeutics' Non-Current Assets stood at $872702.0 in 2019, then soared by 2329.69% to $21.2 million in 2020, then grew by 4.48% to $22.2 million in 2021, then decreased by 19.64% to $17.8 million in 2022, then dropped by 4.35% to $17.0 million in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Non-Current Assets are $17.0 million (Q1 2023), $17.8 million (Q4 2022), and $18.7 million (Q3 2022).